As other companies introduce innovative valve designs and delivery systems, Edwards may face challenges in maintaining its dominant position. Furthermore, the company's growth in the TAVR segment ...

As the company strives to maintain its dominant position in the Transcatheter Aortic Valve Replacement (TAVR) market while expanding into new territories, investors and analysts are closely watching ...

Hospital heart team capacity constraints continued to limit Edwards Lifesciences’ transcatheter aortic valve replacement ...

[Image courtesy of Edwards Lifesciences] Edwards Lifesciences ... Investigators presented data from the transcatheter aortic valve replacement (TAVR) study at Transcatheter Cardiovascular ...

Analysts said the findings complicate the outlook for a U.S. launch of Boston Scientific's aortic valve replacement device.

Edwards Lifesciences Corp., Orange County’s most valuable publicly traded medical device maker, reported third quarter sales ...

With the TAVR market maturing, success in TMTT could provide the company with a new avenue for expansion and revenue growth. Analysts are particularly optimistic about the potential of Edwards' ...